Allo-HSCT With Alternative Donor in Treatment of Hematologic Malignancy

Key facts

Sponsor

Nanfang Hospital, Southern Medical University

Principal Investigator

Qifa Liu

Nanfang Hospital, Southern Medical University

Intervention

HSCT from MSD(procedure)

Enrollment

876 enrolled

Eligibility

18-60 years · All sexes

Timeline

2015 – 2020

Study locations (1)

• Department of Hematology,Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China

Collaborators

Guangdong Provincial People's Hospital · Third Affiliated Hospital, Sun Yat-Sen University · Guangzhou General Hospital of Guangzhou Military Command · Guangzhou First People's Hospital · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Zhujiang Hospital · Tongji Hospital · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Fujian Medical University Union Hospital · First Affiliated Hospital of Guangxi Medical University · Xiangya Hospital of Central South University

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Chronic myeloid leukemia

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE2NCT07354074
  Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP
  Novartis Pharmaceuticals
• RECRUITINGNCT07375355
  Real-world Study of Scemblix in the Treatment of Chronic Myeloid Leukemia in China
  Novartis Pharmaceuticals
• ENROLLING BY INVITATIONNCT07383298
  Observational Study on Dose Optimization of Olverembatinib in Patients With Chronic Myeloid Leukemia in Chronic or Accelerated Phase
  Qian Jiang
• RECRUITINGPHASE2NCT06817720
  Phase II Study Assessing the Efficacy and Toxicity of Olverembatinib Monotherapy in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase
  M.D. Anderson Cancer Center
• RECRUITINGNCT07061145
  A Potential Relationship Between Treatment With Tyrosine Kinase Inhibitors and Erectile Dysfunction in Male Patients With Chronic Myeloid Leukemia
  Azienda USL Reggio Emilia - IRCCS
• RECRUITINGPHASE2NCT06409936
  PEARL Study: PotEntial of Asciminib in the eaRly Treatment of CML
  Gruppo Italiano Malattie EMatologiche dell'Adulto
• RECRUITINGPHASE2NCT06514534
  Open-label Study of Asciminib for CML-CP or CML-AP Patients With T315I Mutation Who Are Resistant, Intolerant or Ineligible to Ponatinib.
  Novartis Pharmaceuticals
• RECRUITINGPHASE1NCT06787144
  ELVN-001 for the Treatment of Chronic Myeloid Leukemia With and Without T315I Mutation in Japanese Participants
  Enliven Therapeutics

See all trials for Chronic myeloid leukemia →